Literature DB >> 25097412

The influence of Imipenem resistant metallo-beta-lactamase positive and negative Pseudomonas aeruginosa nosocomial infections on mortality and morbidity.

Kolhal Veerappa Yogeesha Babu1, Divakara Siddanakatte Visweswaraiah2, Arun Kumar3.   

Abstract

BACKGROUND: Metallo-beta-lactamase (MBL) mediated resistance to carbapenems is an emerging threat in Pseudomonas aeruginosa (PA) nosocomial infections. Limited data on role of Imipenem resistant MBL positive PA (IR-MBLP-PA) and IR-MBL negative-PA (IR-MBLN-PA) infections on mortality and morbidity initiated the present study.
OBJECTIVES: The aim of this study is to determine the role of IR-MBLP-PA and IR-MBLN-PA infections on mortality and morbidity.
MATERIALS AND METHODS: Prospective observational study of 1 year with 110 PA nosocomial infections was conducted with Imipenem + ethylene-diamine-tetra-acetic acid combined disc test for MBL detection. Role of IR-MBLP-PA and IR-MBLN-PA infections on the outcome and morbidity were assessed in terms of crude mortality rate, Charlson's comorbidity score and mean duration of stay in intensive care unit (ICU) until cure and until death, number of episodes of complications and underlying disease. Results were analyzed by z test for proportions and Student t-test.
RESULTS: Relatively high crude mortality was observed among IR-MBLP-PA infections than IR-MBLN-PA (42.86% [6/14] vs. 20% [2/10], Z = 0.69, P = 0.49 NS). Ventilator-associated pneumonia was the underlying disease and a confounding factor in all deaths due to IR-MBLP-PA infections. IR-MBLP-PA infections resulted in rapid downhill course to death with short mean duration of stay in ICU until death than IR-MBLN-PA infections (3.167 ± 0.98 days vs. 16 ± 2.82, P < 0.001 highly significant [HS]) with more number of complications (5.85 ± 1.65 vs. 3.7 ± 1.31, P < 0.001 HS). With the exception of previous Imipenem therapy, association of higher Charlson's comorbidity score, severe underlying diseases, multidrug and pandrug resistance and pre-disposing risk factors with IR-MBLP-PA infections was not statistically significant.
CONCLUSIONS: Higher mortality in IR-MBLP-PA than in IR-MBLN-PA was not significant indicating IR as an important predictor of mortality than MBL production. Higher morbidity and increased virulence was observed with certainty in IR-MBLP-PA infections.

Entities:  

Keywords:  Imipenem resistant metallo-beta-lactamase negative Pseudomonas aeruginosa; imipenem resistant metallo-beta-lactamase positive Pseudomonas aeruginosa; imipenem sensitive Pseudomonas aeruginosa; pre-disposing risk factors

Year:  2014        PMID: 25097412      PMCID: PMC4121912          DOI: 10.4103/0976-9668.136181

Source DB:  PubMed          Journal:  J Nat Sci Biol Med        ISSN: 0976-9668


  13 in total

Review 1.  Emerging carbapenemases in Gram-negative aerobes.

Authors:  P Nordmann; L Poirel
Journal:  Clin Microbiol Infect       Date:  2002-06       Impact factor: 8.067

2.  The influence of metallo-beta-lactamase production on mortality in nosocomial Pseudomonas aeruginosa infections.

Authors:  Alexandre Prehn Zavascki; Afonso Luís Barth; Ana Lúcia Saraiva Gonçalves; Ana Lúcia Didonet Moro; Juliana Fernandez Fernandes; Andreza Francisco Martins; Fabiano Ramos; Luciano Zubaran Goldani
Journal:  J Antimicrob Chemother       Date:  2006-06-03       Impact factor: 5.790

Review 3.  New strategies for combating multidrug-resistant bacteria.

Authors:  Gerard D Wright; Arlene D Sutherland
Journal:  Trends Mol Med       Date:  2007-05-09       Impact factor: 11.951

4.  Population-based epidemiological study of infections caused by carbapenem-resistant Pseudomonas aeruginosa in the Calgary Health Region: importance of metallo-beta-lactamase (MBL)-producing strains.

Authors:  Kevin B Laupland; Michael D Parkins; Deirdre L Church; Daniel B Gregson; Thomas J Louie; John M Conly; Sameer Elsayed; Johann D D Pitout
Journal:  J Infect Dis       Date:  2005-09-26       Impact factor: 5.226

5.  Detection of metallo betalactamase producing Pseudomonas aeruginosa in hospitalized patients.

Authors:  V Hemalatha; Uma Sekar; Vijaylakshmi Kamat
Journal:  Indian J Med Res       Date:  2005-08       Impact factor: 2.375

6.  Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents.

Authors:  Y Carmeli; N Troillet; G M Eliopoulos; M H Samore
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

7.  Emerging resistance to carbapenems in a tertiary care hospital in north India.

Authors:  Ekta Gupta; Srujana Mohanty; Seema Sood; Benu Dhawan; Bimal K Das; Arti Kapil
Journal:  Indian J Med Res       Date:  2006-07       Impact factor: 2.375

Review 8.  Antimicrobial treatment of ventilator-associated pneumonia.

Authors:  David R Park
Journal:  Respir Care       Date:  2005-07       Impact factor: 2.258

9.  CDC definitions for nosocomial infections, 1988.

Authors:  J S Garner; W R Jarvis; T G Emori; T C Horan; J M Hughes
Journal:  Am J Infect Control       Date:  1988-06       Impact factor: 2.918

10.  Clinical and bacteriological characteristics of IMP-type metallo-beta-lactamase-producing Pseudomonas aeruginosa.

Authors:  Yoichi Hirakata; Toshiyuki Yamaguchi; Michiko Nakano; Koichi Izumikawa; Mariko Mine; Shiho Aoki; Akira Kondoh; Junichi Matsuda; Mitsukuni Hirayama; Katsunori Yanagihara; Yoshitsugu Miyazaki; Kazunori Tomono; Yasuaki Yamada; Shimeru Kamihira; Shigeru Kohno
Journal:  Clin Infect Dis       Date:  2003-06-24       Impact factor: 9.079

View more
  3 in total

1.  Systematic review and meta-analysis of imipenem-resistant Pseudomonas aeruginosa prevalence in Iran.

Authors:  Hamid Vaez; Amin Salehi-Abargouei; Farzad Khademi
Journal:  Germs       Date:  2017-06-01

Review 2.  How to manage Pseudomonas aeruginosa infections.

Authors:  Matteo Bassetti; Antonio Vena; Antony Croxatto; Elda Righi; Benoit Guery
Journal:  Drugs Context       Date:  2018-05-29

3.  Clonal Relatedness among Imipenem-Resistant Pseudomonas aeruginosa Isolated from ICU-Hospitalized Patients.

Authors:  Hamid Vaez; Sharareh Moghim; Bahram Nasr Esfahani; Hajieh Ghasemian Safaei
Journal:  Crit Care Res Pract       Date:  2015-12-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.